Funds and ETFs Haleon plc

Equities

HLN

GB00BMX86B70

Pharmaceuticals

Real-time Estimate Cboe Europe 06:43:16 2024-05-31 EDT 5-day change 1st Jan Change
324.8 GBX +0.02% Intraday chart for Haleon plc +0.34% +0.76%

ETFs positioned on Haleon plc

Name Weight AuM 1st Jan change Investor Rating
1.35% 142 M€ +12.47% -
0.99% 11 M€ +0.83% -
0.94% 5 M€ +15.29%
0.21% 48 M€ +8.59%
0.17% 6 M€ -.--%
0.12% 10 M€ -3.35% -
0.11% 2 M€ +9.19% -
0.11% 2 M€ -.--% -
0.09% 32 M€ +6.51% -
0.09% 7 M€ +4.71% -
0.08% 727 M€ +7.44%
0.04% 205 M€ -.--%
0.04% 1,166 M€ +0.26% -
0.04% 607 M€ +0.05% -
0.03% 0 M€ 0.00% -
0.03% 391 M€ +7.86% -
0.02% 34 M€ +8.09% -
0.02% 306 M€ +5.09% -
0.02% 39 M€ +5.33% -
0.01% 105 M€ +3.05% -
0.01% 34 M€ +3.93% -
0.01% 234 M€ +9.09% -
0.01% 54 M€ +0.13% -
0.00% 7 M€ +0.11% -
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.247 GBP
Average target price
3.62 GBP
Spread / Average Target
+11.49%
Consensus
  1. Stock Market
  2. Equities
  3. HLN Stock
  4. Funds and ETFs Haleon plc